Cagrilintide

Background

Cagrilintide is a long-acting amylin analog developed for obesity and, in combination studies, type 2 diabetes-related weight management. It was originally known in development as AM833 and was designed to overcome the short half-life and formulation limitations of native amylin while preserving satiety and postprandial glucose-lowering biology[8][12][13]. Amylin is co-secreted with insulin from pancreatic beta cells and acts as a satiety hormone with effects on gastric emptying, glucagon suppression, and central appetite regulation[1][2].

The therapeutic rationale for cagrilintide emerged from the broader amylin drug-development program that first validated the class with pramlintide and then advanced longer-acting analogs for once-weekly use[8][12]. Cagrilintide is notable as one of the first amylin-based agents to achieve clinically meaningful body-weight reduction as monotherapy in obesity trials, and it has become especially important as a partner for GLP-1 receptor agonist combinations[1][2][8].

Mechanism of action

Cagrilintide is described in the literature as a dual amylin receptor/calcitonin receptor agonist with amylin-like binding properties[8][11][12]. Amylin receptors are formed by calcitonin receptor isoforms complexed with receptor activity-modifying proteins (RAMPs), and the receptor pharmacology is structurally and functionally related to the calcitonin peptide family[11][13]. The most relevant receptor complexes for amylin-like signaling are AMY1, AMY2, and AMY3, with downstream signaling in hindbrain and hypothalamic pathways that modulate satiety and food intake[11][13].

Functionally, cagrilintide is intended to reduce energy intake through central appetite suppression, while also influencing gastric emptying and prandial glucagon regulation, consistent with the class effects of amylin agonism[1][2][12]. Structural work has shown that cagrilintide engages calcitonin and amylin receptors in an amylin-like manner, supporting its classification as a long-acting amylin pathway agonist rather than a simple pramlintide analogue[11].

Evidence summary

Preclinical studies supporting the class show that long-acting amylin analogs can drive sustained appetite reduction and weight loss in rodents and nonhuman primates, with fatty-acid conjugation used to extend half-life and improve self-association/PK behavior[7][9][10]. In one medicinal chemistry study of a new long-acting amylin receptor agonist, cagrilintide served as the comparator and showed potency in amylin receptor assays and measurable weight reduction in rats and cynomolgus monkeys in the broader discovery program[9]. These data support the translational logic of the molecule, although most mechanistic preclinical findings are class-level rather than cagrilintide-specific.

Clinical evidence is substantially more developed. A phase 1 obesity program established once-weekly cagrilintide as a viable amylin analog, and later phase 2 studies showed clinically meaningful weight loss. In the most cited obesity trial, 12-week cagrilintide monotherapy in adults with overweight or obesity produced dose-dependent body-weight reduction versus placebo, with the highest-dose arms achieving approximately 10% weight loss over the study period in published reports summarized by reviews[1][2][8][12]. Exact cohort sizes vary by dose cohort and publication format, but the trial is widely cited as proof-of-concept for once-weekly amylin-based obesity pharmacotherapy[1][2][8].

The combination program has been especially influential. In the phase 2 study of CagriSema (cagrilintide plus semaglutide) in people with type 2 diabetes, the combination produced greater weight loss and improved glycemic outcomes than semaglutide or cagrilintide-based comparators, with the publicly summarized report describing a short phase 2 trial and clearly superior efficacy for the combination[5][2][8]. Reviews consistently cite this as evidence for additive or complementary appetite suppression when amylin and GLP-1 pathways are co-targeted[1][2][8].

Clinical and research uses

Cagrilintide remains investigational and is being developed primarily for obesity, with adjunctive research in type 2 diabetes and related metabolic disease contexts[2][8][12]. Its clearest clinical niche is as a once-weekly injectable anti-obesity agent, either alone or paired with semaglutide in fixed or co-formulated combination strategies[2][5][8].

Research use has expanded to mechanistic studies of receptor pharmacology, peptide aggregation, and co-formulation with incretin-based therapies[11][7][9]. The broader amylin literature also positions cagrilintide as a platform molecule for next-generation multi-agonist combinations and comparison against other emerging long-acting amylin analogs[8][10][14].

Dosing context

Published studies and reviews describe cagrilintide as a once-weekly subcutaneous agent[2][8][12]. Clinical development has evaluated dose-escalation and fixed weekly dosing schedules, with commonly reported research doses in the sub-milligram to multi-milligram range depending on indication and combination regimen[1][2][5][8]. In obesity monotherapy and CagriSema studies, weekly maintenance dosing has generally been the central design feature, but dose selection has varied across trials and publications[2][5][8].

No approved labeled dose exists in the US or EU, and literature dosing should be interpreted strictly as investigational rather than prescriptive[2][8].

Safety profile

Across published trials and reviews, the most common adverse effects are gastrointestinal, especially nausea, vomiting, decreased appetite, and constipation, which are consistent with amylin-pathway activation and with the tolerability profile of weight-loss incretin therapies[2][8][12]. These effects appear to be dose-related and often most prominent during initiation or escalation phases[2][5][8].

Because cagrilintide can delay gastric emptying and reduce intake, clinically relevant concerns include dehydration and reduced oral intake in susceptible patients, although detailed long-term safety data remain limited[1][2][8]. Reviews emphasize that the evidence base is still relatively early, so less common risks, duration-related tolerability issues, and comparative safety versus other anti-obesity agents remain incompletely characterized[2][8][12].

Formal contraindications have not yet been established in a product label because no approved label exists. In clinical-trial practice, expected exclusions have generally followed class-based considerations for investigational anti-obesity drugs, including pregnancy and medically unstable conditions, but these are trial-specific rather than cagrilintide-specific regulatory contraindications[2][8].

Regulatory status

Cagrilintide has no approved indication in the United States or the European Union as of the latest peer-reviewed and review literature available here[2][8][12]. It remains an investigational drug in clinical development, most prominently for obesity and in fixed-combination programs with semaglutide[2][5][8]. Publicly available sources reviewed here do not identify FDA approval or EMA marketing authorization for cagrilintide itself[2][8].